HIGH-RISK MYELODYSPLASTIC SYNDROMES
Clinical trials for HIGH-RISK MYELODYSPLASTIC SYNDROMES explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK MYELODYSPLASTIC SYNDROMES trials appear
Sign up with your email to follow new studies for HIGH-RISK MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough blood cancers
Disease control Recruiting nowThis phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…
Matched conditions: HIGH-RISK MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to stop blood cancer relapse after transplant
Disease control Recruiting nowThis study tests whether adding the targeted drug venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 6…
Matched conditions: HIGH-RISK MYELODYSPLASTIC SYNDROMES
Phase: NA • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 26, 2026 19:12 UTC